Dr. Reddy’s Laboratories Limited (NYSE:RDY) Forecasted to Earn FY2027 Earnings of $3.12 Per Share

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research decreased their FY2027 EPS estimates for shares of Dr. Reddy’s Laboratories in a research report issued on Wednesday, September 11th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $3.12 for the year, down from their previous estimate of $3.15. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $4.11 per share.

Separately, Barclays upped their price objective on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th.

Dr. Reddy’s Laboratories Stock Performance

RDY stock opened at $80.37 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The firm has a market cap of $13.42 billion, a PE ratio of 19.94, a P/E/G ratio of 1.74 and a beta of 0.55. The business has a 50 day moving average of $81.05 and a 200-day moving average of $75.61. Dr. Reddy’s Laboratories has a 12-month low of $63.72 and a 12-month high of $84.46.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). The firm had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million. Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

A number of hedge funds have recently modified their holdings of the stock. Creative Planning increased its holdings in Dr. Reddy’s Laboratories by 22.6% in the 2nd quarter. Creative Planning now owns 87,522 shares of the company’s stock worth $6,668,000 after acquiring an additional 16,157 shares during the last quarter. Millennium Management LLC increased its stake in shares of Dr. Reddy’s Laboratories by 61.4% in the second quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock worth $25,333,000 after purchasing an additional 126,472 shares in the last quarter. Bank of Montreal Can raised its position in shares of Dr. Reddy’s Laboratories by 75.4% in the second quarter. Bank of Montreal Can now owns 9,918 shares of the company’s stock valued at $758,000 after purchasing an additional 4,262 shares during the period. Frank Rimerman Advisors LLC purchased a new stake in shares of Dr. Reddy’s Laboratories during the 2nd quarter valued at approximately $2,633,000. Finally, Profund Advisors LLC boosted its holdings in Dr. Reddy’s Laboratories by 5.7% in the 2nd quarter. Profund Advisors LLC now owns 8,198 shares of the company’s stock worth $625,000 after buying an additional 445 shares during the period. Institutional investors own 14.02% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.